Full text
| |
| Author(s): |
Elisa Napolitano e Ferreira
Total Authors: 1
|
| Document type: | Doctoral Thesis |
| Press: | São Paulo. |
| Institution: | Universidade de São Paulo (USP). Instituto de Biociências (IBIOC/SB) |
| Defense date: | 2010-09-16 |
| Examining board members: |
Dirce Maria Carraro;
Lygia da Veiga Pereira Carramaschi;
Emmanuel Dias Neto;
Luciana Amaral Haddad;
Paulo Sérgio Lopes de Oliveira
|
| Advisor: | Dirce Maria Carraro |
| Abstract | |
Alternative splicing is a process, by which many differente transcripts can be generated by one single gene, significantly expanding the transcriptional and proteomic diversity. Different splicing variants are generated among different transcripts and developmental stages, assuring normal cell function. Therefore, alterations in the splicing process can lead to diseases outcome. In this context, the aim of this study was the establishment of methodologies for the identification of alternative splicing in breast cancer influenced by ERBB2 oncogene, which is a poor prognostic molecular marker, highly expressed in 30% of human breast cancer. Two strategies were established for the construction of cDNA libraries. Alternative enriched splicing libraries, based on heteroduplex capture combined with mRNA amplification, were constructed from total RNA from a cell line and also from five tumor samples, all of them presenting high ERBB2 expression. Seventy nine putative splicing variants were identified and 18 of them were selected for RT-PCR validation. A high validation level was obtained (94%) and two novel alternative splicing variants were identified. ERBB2 mediated regulation was confirmed for three variants by two distinct methodologies, electrophoresis on a chip and probe specific ligation approach. The alteration in the expression balance of variants suggests the influence of the oncogene in the splicing pattern regulation. The second strategy was the construction of cDNA libraries for global transcriptome analysis based on deep sequencing. Total RNA from two mammary epithelial cell lines expressing different ERBB2 levels were used and 2,865 novel splicing variants were identified. Twenty novel events reporting the inclusion of novel exons were selected for RT-PCR validation with 90% validation rate. Six variants presented higher expression in the cell line with high levels of ERBB2. Moreover enrichment in splicing events was detected in the ERBB2 high expressing cell line, supporting the ERBB2 influence in alternative splicing regulation, possibly resulting in splicing variants associated to this subgroup of cancer that can be tested as molecular markers. (AU) | |